Clinical trial
Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix
NCT00430144 · Sokbom Kang, Other · Completed
Key facts
| NCT number | NCT00430144 |
|---|---|
| Title | Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix |
| Official title | A Phase II Study of Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix |
| Lead sponsor | Sokbom Kang, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer |
| Intervention type | Drug |
| Interventions | Belotecan(CKD-602) |
| Enrollment | 16 |
| Start date | Jan 1, 2007 |
| Primary completion | Aug 1, 2009 |
| Completion | Oct 1, 2010 |
| First posted | Feb 1, 2007 |
| Last update posted | Apr 26, 2012 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: